BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49:832-838. [PMID: 19152426 DOI: 10.1002/hep.22693] [Cited by in Crossref: 240] [Cited by in F6Publishing: 222] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Orci LA, Lacotte S, Oldani G, Slits F, De Vito C, Crowe LA, Rubbia-Brandt L, Vallée JP, Morel P, Toso C. Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis. Br J Surg 2016;103:417-26. [PMID: 26891212 DOI: 10.1002/bjs.10080] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
2 Togashi J, Akamastu N, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital. Hepatobiliary Surg Nutr. 2016;5:399-407. [PMID: 27826554 DOI: 10.21037/hbsn.2016.08.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
3 Maggs JRL, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1113-34. [DOI: 10.1111/j.1365-2036.2012.05072.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
4 Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology 2019;69:1324-36. [DOI: 10.1002/hep.30278] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
5 Doganay L. Hepatocellular Cancer: Is Recurrence Inevitable? J Gastrointest Cancer 2017;48:274-5. [PMID: 28647821 DOI: 10.1007/s12029-017-9967-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kaido T. Selection Criteria and Current Issues in Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer 2016;5:121-7. [PMID: 27386430 DOI: 10.1159/000367749] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yoon JH, Lee WJ, Kim SM, Kim KT, Cho SB, Kim HJ, Ko YS, Kook HY, Jun CH, Choi SK, Kim BS, Cho SY, You HS, Lee Y, Son S. Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Sci Rep 2021;11:12984. [PMID: 34155324 DOI: 10.1038/s41598-021-92503-6] [Reference Citation Analysis]
8 Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Burroughs AK. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl. 2011;17 Suppl 2:S58-S66. [PMID: 21584928 DOI: 10.1002/lt.22336] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
9 Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R. Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival. Can J Gastroenterol 2011;25:426-32. [PMID: 21912767 DOI: 10.1155/2011/864234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
10 Greig PD, Geier A, D'Alessandro AM, Campbell M, Wright L. Should we perform deceased donor liver transplantation after living donor liver transplantation has failed? Liver Transpl 2011;17 Suppl 2:S139-46. [PMID: 21563294 DOI: 10.1002/lt.22328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Qu Z, Ling Q, Gwiasda J, Xu X, Schrem H, Beneke J, Kaltenborn A, Krauth C, Mix H, Klempnauer J, Emmanouilidis N. Hangzhou criteria are more accurate than Milan criteria in predicting long-term survival after liver transplantation for HCC in Germany. Langenbecks Arch Surg 2018;403:643-54. [PMID: 30120543 DOI: 10.1007/s00423-018-1696-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
12 Siparsky N, Axelrod D, Freeman RB. Organ Allocation in Liver Transplantation: Ethics, Organ Supply, and Evidencebased Practice. In: Clavien P, Trotter JF, editors. Medical Care of the Liver Transplant Patient. Oxford: Wiley-Blackwell; 2012. pp. 75-87. [DOI: 10.1002/9781444398441.ch7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Macaron C, Hanouneh IA, Lopez R, Aucejo F, Zein NN. Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc. 2010;42:4585-4592. [PMID: 21168743 DOI: 10.1016/j.transproceed.2010.10.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
14 Kim Y, Stahl CC, Makramalla A, Olowokure OO, Ristagno RL, Dhar VK, Schoech MR, Chadalavada S, Latif T, Kharofa J, Bari K, Shah SA. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery. 2017;162:1250-1258. [PMID: 29033224 DOI: 10.1016/j.surg.2017.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
15 Kaido T, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T, Uemoto S. Recurrence of hepatocellular carcinoma after living donor liver transplantation: what is the current optimal approach to prevent recurrence? World J Surg 2011;35:1355-9. [PMID: 21424873 DOI: 10.1007/s00268-011-1045-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Kim SH, Moon DB, Kim WJ, Kang WH, Kwon JH, Jwa EK, Cho HD, Ha SM, Chung YK, Lee SG. Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. Hepatobiliary Surg Nutr 2016;5:461-9. [PMID: 28124000 DOI: 10.21037/hbsn.2016.11.05] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
17 Lee SD, Kim SH, Kim SK, Kim YK, Park SJ. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma. Transplantation. 2015;99:2142-2149. [PMID: 25905981 DOI: 10.1097/tp.0000000000000719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
18 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Toso C, Andres A, Kneteman N, Hernandez-Alejandro R, Majno P. Alpha-foetoprotein: further evidence to add a biological marker to refine Milan criteria. Liver Int 2016;36:1580-1. [PMID: 27744652 DOI: 10.1111/liv.13184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Li WX, Li Z, Gao PJ, Gao J, Zhu JY. Histological differentiation predicts post-liver transplantation survival time. Clin Res Hepatol Gastroenterol. 2014;38:201-208. [PMID: 24388339 DOI: 10.1016/j.clinre.2013.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhou J, Hu Z, Li Z, Yu P, Wu J, Zheng S. The role of liver cancer stem cells in donor liver allocation for patients with hepatocellular carcinoma. Postgrad Med 2013;125:24-30. [PMID: 24200758 DOI: 10.3810/pgm.2013.11.2709] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Pruinelli L, Monsen KA, Gross CR, Radosevich DM, Simon GJ, Westra BL. Predictors of Liver Transplant Patient Survival: A Critical Review Using a Holistic Framework. Prog Transpl 2017;27:98-106. [DOI: 10.1177/1526924816680099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Casadei-Gardini A, Orsi G, Caputo F, Ercolani G. Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Rev Anticancer Ther 2020;20:63-74. [PMID: 31910040 DOI: 10.1080/14737140.2020.1712198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
24 Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108-117. [PMID: 20451283 DOI: 10.1016/j.jhep.2010.01.038] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 9.6] [Reference Citation Analysis]
25 Lai Q, Castro Santa E, Rico Juri JM, Pinheiro RS, Lerut J. Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int. 2014;27:32-41. [PMID: 24118272 DOI: 10.1111/tri.12191] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 10.3] [Reference Citation Analysis]
26 Lei JY, Wang WT, Yan LN. “Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol. 2013;19:8093-8098. [PMID: 24307805 DOI: 10.3748/wjg.v19.i44.8093] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
27 Wang LY, Zheng SS. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ Sci B 2018;19:497-504. [PMID: 29971988 DOI: 10.1631/jzus.B1700156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
28 Piñero F, Marciano S, Anders M, Orozco Ganem F, Zerega A, Cagliani J, Andriani O, de Santibañes E, Gil O, Podestá LG, Mccormack L, Gadano A, Silva M. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina: . European Journal of Gastroenterology & Hepatology 2016;28:421-7. [DOI: 10.1097/meg.0000000000000551] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
29 Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, Franceschet E, Germani G, Senzolo M, Romano A, Angeli P, Rugge M, Farinati F, Forton DM, Cillo U, Burra P, Russo FP. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl. 2017;23:1103-1112. [PMID: 28544587 DOI: 10.1002/lt.24790] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
30 Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814-819. [PMID: 21334400 DOI: 10.1016/j.jhep.2010.12.040] [Cited by in Crossref: 119] [Cited by in F6Publishing: 104] [Article Influence: 11.9] [Reference Citation Analysis]
31 Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl. 2013;19:634-645. [PMID: 23536495 DOI: 10.1002/lt.23652] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 13.0] [Reference Citation Analysis]
32 Uemura T, Kirichenko A, Bunker M, Vincent M, Machado L, Thai N. Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation. World J Surg 2019;43:886-93. [PMID: 30361748 DOI: 10.1007/s00268-018-4829-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
33 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 36.5] [Reference Citation Analysis]
34 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9.] [Reference Citation Analysis]
35 Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope; 7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018;102:816-822. [PMID: 29505494 DOI: 10.1097/tp.0000000000002094] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
36 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol. 2015;7:1184-1191. [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
37 Wu J, Zhou X, Li P, Lin X, Wang J, Hu Z, Zhang P, Chen D, Cai H, Niessner R, Haisch C, Sun P, Zheng Y, Jiang Z, Zhou H. Ultrasensitive and Simultaneous SERS Detection of Multiplex MicroRNA Using Fractal Gold Nanotags for Early Diagnosis and Prognosis of Hepatocellular Carcinoma. Anal Chem 2021;93:8799-809. [PMID: 34076420 DOI: 10.1021/acs.analchem.1c00478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
38 Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011;100:22-9. [PMID: 21482502 DOI: 10.1177/145749691110000105] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
39 Toso C, Majno P, Berney T, Morel P, Mentha G, Combescure C. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list. Transpl Int. 2014;27:686-695. [PMID: 24649861 DOI: 10.1111/tri.12323] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
40 Zhang W, Kim R, Quintini C, Hashimoto K, Fujiki M, Diago T, Eghtesad B, Miller C, Fung J, Tan A. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation. Liver Transpl. 2015;21:101-111. [PMID: 25283528 DOI: 10.1002/lt.24013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
41 Belghiti J, Durand F. Criteria for liver transplantation for hepatocellular carcinoma: what is an acceptable outcome? Liver Int. 2011;31 Suppl 1:161-163. [PMID: 21205155 DOI: 10.1111/j.1478-3231.2010.02413.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
42 Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience. European Journal of Gastroenterology & Hepatology 2014;26:200-4. [DOI: 10.1097/meg.0b013e3283652b66] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
43 Qin W, Wang L, Hu B, Leng S, Tian H, Luo H, Yao J, Chen X, Wu C, Chen G, Yang Y. A Novel Score Predicts HBV-Related Hepatocellular Carcinoma Recurrence After Hepatectomy: a Retrospective Multicenter Study. J Gastrointest Surg 2019;23:922-32. [PMID: 30446938 DOI: 10.1007/s11605-018-4037-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Melloul E, Lesurtel M, Carr BI, Clavien PA. Developments in liver transplantation for hepatocellular carcinoma. Semin Oncol. 2012;39:510-521. [PMID: 22846868 DOI: 10.1053/j.seminoncol.2012.05.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
45 Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010;24:643-50. [PMID: 21157578 DOI: 10.1155/2010/410574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
46 Murali AR, Romero-marrero C, Miller C, Aucejo F, Levitin A, Gill A, Mclennan G, Karuppasamy K, Zein NN, Lopez R, Menon KN. Predictors of Successful Downstaging of Hepatocellular Carcinoma Outside Milan Criteria. Transplantation 2016;100:2391-7. [DOI: 10.1097/tp.0000000000001402] [Cited by in Crossref: 12] [Article Influence: 2.4] [Reference Citation Analysis]
47 Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol. 2017;23:3690-3701. [PMID: 28611522 DOI: 10.3748/wjg.v23.i20.3690] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
48 Huo TI, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Chiang JH, Lee PC, Lee SD. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol 2010;10:146. [PMID: 21194431 DOI: 10.1186/1471-230X-10-146] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
49 Alim A, Erdogan Y, Dayangac M, Yuzer Y, Tokat Y, Oezcelik A. Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria. Cancer Control 2021;28:10732748211011960. [PMID: 33926242 DOI: 10.1177/10732748211011960] [Reference Citation Analysis]
50 Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, Jung DH, Park GC, Yoon YI, Lee SG. Quantitative Prognostic Prediction Using ADV Score for Hepatocellular Carcinoma Following Living Donor Liver Transplantation. J Gastrointest Surg 2021. [PMID: 33532981 DOI: 10.1007/s11605-021-04939-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
51 Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S;  Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int. 2019;32:356-368. [PMID: 30556935 DOI: 10.1111/tri.13391] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
52 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017;23:3195-204. [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Vitale A, Cucchetti A, Qiao GL, Cescon M, Li J, Ramirez Morales R, Frigo AC, Xia Y, Tuci F, Shen F, Cillo U, Pinna AD. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit. J Hepatol. 2014;60:1165-1171. [PMID: 24508550 DOI: 10.1016/j.jhep.2014.01.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
54 Lai Q, Avolio AW, Manzia TM, Sorge R, Agnes S, Tisone G, Berloco PB, Rossi M. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant. 2012;26:E125-E131. [PMID: 22192083 DOI: 10.1111/j.1399-0012.2011.01572.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
55 Burra P, Zanetto A, Germani G. Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E46. [PMID: 29425151 DOI: 10.3390/cancers10020046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
56 Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci. 2012;57:806-812. [PMID: 21953139 DOI: 10.1007/s10620-011-1910-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
57 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A;  OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9] [Cited by in Crossref: 600] [Cited by in F6Publishing: 221] [Article Influence: 60.0] [Reference Citation Analysis]
58 Andres A, Oldani G, Berney T, Compagnon P, Line PD, Toso C. Transplantation for colorectal metastases: on the edge of a revolution. Transl Gastroenterol Hepatol. 2018;3:74. [PMID: 30363763 DOI: 10.21037/tgh.2018.08.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
59 Tsoulfas G, Agorastou P, Tooulias A, Marakis GN. Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review. Int Surg 2014;99:779-86. [PMID: 25437587 DOI: 10.9738/INTSURG-D-13-00122.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, Teperman LW, Park JS, Kim YJ, Suh KS, Yoon JH. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Ann Surg. 2016;263:842-850. [PMID: 26779979 DOI: 10.1097/sla.0000000000001578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 24] [Article Influence: 11.8] [Reference Citation Analysis]
61 Degroote H, Callebout E, Iesari S, Dekervel J, Schreiber J, Pirenne J, Verslype C, Ysebaert D, Michielsen P, Lucidi V, Moreno C, Detry O, Delwaide J, Troisi RI, Lerut JP, Van Vlierberghe H; Be-LIAC. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surg Oncol 2020;33:231-8. [PMID: 31630912 DOI: 10.1016/j.suronc.2019.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Toso C, Mazzaferro V, Bruix J, Freeman R, Mentha G, Majno P. Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant. 2014;14:2221-2227. [PMID: 25220672 DOI: 10.1111/ajt.12923] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 6.1] [Reference Citation Analysis]
63 Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation: Monitoring Patients with Hepatocellular Carcinoma. Liver Transpl 2011;17:S117-27. [DOI: 10.1002/lt.22334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
64 Dufour J, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho R. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Annals of Oncology 2013;24:24-9. [DOI: 10.1093/annonc/mdt054] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
65 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Machaca MP, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Fauda M, McCormack L, Gadano A, Boin IS, García JHP, Silva M. Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study. Ann Hepatol 2018;17:256-67. [PMID: 29469048 DOI: 10.5604/01.3001.0010.8648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, Thung SN, Tan PS, Dong H, Revill K, Chang CY, Roayaie S, Byrne TJ, Mazzaferro V, Rakela J, Florman S, Schwartz M, Llovet JM. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. Journal of Hepatology 2015;63:1368-77. [DOI: 10.1016/j.jhep.2015.07.025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
67 Ciccarelli O, Lai Q, Goffette P, Finet P, De Reyck C, Roggen F, Sempoux C, Doffagne E, Reding R, Lerut J. Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int. 2012;25:867-875. [PMID: 22716073 DOI: 10.1111/j.1432-2277.2012.01512.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
68 Wang LY, Zheng SS, Xu X, Wang WL, Wu J, Zhang M, Shen Y, Yan S, Xie HY, Chen XH, Jiang TA, Chen F. A score model for predicting post-liver transplantation survival in HBV cirrhosis-related hepatocellular carcinoma recipients: a single center 5-year experience. Hepatobiliary Pancreat Dis Int 2015;14:43-9. [PMID: 25655289 DOI: 10.1016/s1499-3872(15)60335-6] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
69 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1663] [Article Influence: 707.3] [Reference Citation Analysis]
70 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016;8:58-68. [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
71 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118. [PMID: 24945001 DOI: 10.1159/000343866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
72 Tschuor C, Ferrarese A, Kuemmerli C, Dutkowski P, Burra P, Clavien PA;  Liver Allocation Study Group. Allocation of liver grafts worldwide - Is there a best system? J Hepatol. 2019;71:707-718. [PMID: 31199941 DOI: 10.1016/j.jhep.2019.05.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 15.0] [Reference Citation Analysis]
73 Farinati F, Giacomin A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy. European Journal of Gastroenterology & Hepatology 2012;24:195-202. [DOI: 10.1097/meg.0b013e32834e153c] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
74 Na BG, Kim YK, Hwang S, Lee KJ, Park GC, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Yang H, Yoon YI, Tak E, Park YH, Lee SG. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e25640. [PMID: 33907121 DOI: 10.1097/MD.0000000000025640] [Reference Citation Analysis]
75 Manini MA, Sangiovanni A, Martinetti L, Viganò D, La Mura V, Aghemo A, Iavarone M, Crespi S, Nicolini A, Colombo M. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma. Liver Transpl. 2015;21:1259-1269. [PMID: 26074360 DOI: 10.1002/lt.24196] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
76 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
77 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. WJCO 2021;12:623-45. [DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
78 Ho M, Yu C, Chung K, Chen T, Chu H, Lin C, Hsieh C. Locoregional Therapy-Induced Tumor Necrosis as a Predictor of Recurrence after Liver Transplant in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2011;18:3632-9. [DOI: 10.1245/s10434-011-1803-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
79 Wong LL, Naugler WE, Schwartz J, Scott DL, Bhattacharya R, Reyes J, Orloff SL. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis. Clin Transplant. 2013;27:E72-E79. [PMID: 23278701 DOI: 10.1111/ctr.12056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
80 Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987-999. [PMID: 22429190 DOI: 10.1111/j.1365-2036.2012.05060.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
81 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
82 Aziz S, Sey M, Marotta P, Driman D, Parfitt J, Teriaky A, Brahmania M, Skaro A, Qumosani K. Recurrent Hepatocellular Carcinoma After Liver Transplantation: Validation of a Pathologic Risk Score on Explanted Livers to Predict Recurrence. Transplant Proc 2021;53:1975-9. [PMID: 34272052 DOI: 10.1016/j.transproceed.2021.05.007] [Reference Citation Analysis]
83 Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22:309-18. [PMID: 27729631 DOI: 10.3350/cmh.2016.0042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
84 Duvoux C, Roudot–thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard P, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux G, Chazouillères O, Salame E, Hilleret M, Lebray P, Abergel A, Debette–gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology 2012;143:986-994.e3. [DOI: 10.1053/j.gastro.2012.05.052] [Cited by in Crossref: 438] [Cited by in F6Publishing: 381] [Article Influence: 48.7] [Reference Citation Analysis]
85 Kaido T, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T, Yagi S, Uemoto S. Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection. Surgery. 2012;151:55-60. [PMID: 21943635 DOI: 10.1016/j.surg.2011.06.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
86 Montano-Loza AJ, Mazurak VC, Ebadi M, Meza-Junco J, Sawyer MB, Baracos VE, Kneteman N. Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology 2018;67:914-23. [PMID: 29023899 DOI: 10.1002/hep.29578] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
87 Lee YH, Hsia CY, Hsu CY, Huang YH, Lin HC, Huo TI. Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria. World J Surg 2013;37:1348-55. [PMID: 23467925 DOI: 10.1007/s00268-013-1978-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
88 Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology. 2012;56:149-156. [PMID: 22271250 DOI: 10.1002/hep.25603] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 8.2] [Reference Citation Analysis]
89 Ma KW, Cheung TT. When to consider liver transplantation in hepatocellular carcinoma patients? Hepat Oncol. 2017;4:15-24. [PMID: 30191050 DOI: 10.2217/hep-2016-0010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
90 Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, Del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI, Jara P, Morales JM, Navarro M, Oppenheimer F, Prieto M, Pulpón LA, Rimola A, Román A, Serón D, Ussetti P; ATOS Working Group. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando) 2012;26:261-79. [PMID: 22902168 DOI: 10.1016/j.trre.2012.07.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
91 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
92 Takada Y, Tohyama T, Watanabe J. Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci 2015;22:279-86. [PMID: 25408520 DOI: 10.1002/jhbp.195] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
93 Tsai Y, Hsu C, Huang Y, Su C, Lin H, Lee R, Chiang J, Huo T, Lee S. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011;5:975-84. [DOI: 10.1007/s12072-011-9276-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
94 Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-uso T, Quintini C, Eghtesad B, Fung JJ, Aucejo FN, Miller CM. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. The Lancet Gastroenterology & Hepatology 2017;2:595-603. [DOI: 10.1016/s2468-1253(17)30106-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
95 Hwang S, Ahn C, Kim K, Moon D, Ha T, Song G, Jung D, Park G, Yu Y, Park P, Choi Y, Kim K, Lim Y, Lee HC, Yu E, Lee S. Super-selection of a Subgroup of Hepatocellular Carcinoma Patients at Minimal Risk of Recurrence for Liver Transplantation. J Gastrointest Surg 2011;15:971-81. [DOI: 10.1007/s11605-011-1467-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
96 Toniutto P, Bitetto D, Fornasiere E, Fumolo E. Challenges and future developments in liver transplantation. Minerva Gastroenterol Dietol 2019;65:136-52. [PMID: 30303340 DOI: 10.23736/S1121-421X.18.02529-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
97 Kaido T, Takada Y, Uemoto S. Selection Criteria for Patients With Hepatocellular Carcinoma in Liver Transplantation. Transplantation 2009;88:442-3. [DOI: 10.1097/tp.0b013e3181af385a] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl. 2013;19:1214-1223. [PMID: 23907778 DOI: 10.1002/lt.23715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
99 Ramos Rubio E, Ortiz de Urbina J, Santoyo Santoyo J, Varo Pérez E. Grado de homogeneidad de los grupos españoles de trasplante hepático en el tratamiento del hepatocarcinoma. Medicina Clínica 2013;141:406-10. [DOI: 10.1016/j.medcli.2013.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
100 Roayaie K, Roayaie S. Liver transplant for hepatocellular cancer: very small tumors, very large tumors, and waiting time. Clin Liver Dis. 2014;18:603-612. [PMID: 25017078 DOI: 10.1016/j.cld.2014.05.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016;8:881-90. [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
102 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 2015;7:673-687. [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
103 Lai Q, Avolio AW, Manzia TM, Agnes S, Tisone G, Berloco PB, Rossi M. Role of alpha-fetoprotein in selection of patients with hepatocellular carcinoma waiting for liver transplantation: must we reconsider it? Int J Biol Markers. 2011;26:153-159. [PMID: 21928243 DOI: 10.5301/jbm.2011.8557] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
104 Gundlach JP, Schmidt S, Bernsmeier A, Günther R, Kataev V, Trentmann J, Schäfer JP, Röcken C, Becker T, Braun F. Indication of Liver Transplantation for Hepatocellular Carcinoma Should Be Reconsidered in Case of Microvascular Invasion and Multilocular Tumor Occurrence. J Clin Med 2021;10:1155. [PMID: 33801887 DOI: 10.3390/jcm10061155] [Reference Citation Analysis]
105 El Moghazy W, Kashkoush S, Meeberg G, Kneteman N. Incidence, Characteristics, and Prognosis of Incidentally Discovered Hepatocellular Carcinoma after Liver Transplantation. J Transplant 2016;2016:1916387. [PMID: 27403337 DOI: 10.1155/2016/1916387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
106 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 316] [Article Influence: 121.7] [Reference Citation Analysis]
107 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Lai Q, Levi Sandri GB, Lerut J. Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm. World J Hepatol. 2015;7:1899-1904. [PMID: 26244064 DOI: 10.4254/wjh.v7.i15.1899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol 2016;22:3325-34. [PMID: 27022214 DOI: 10.3748/wjg.v22.i12.3325] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
110 Wang W, Ye Y, Wang T, Zhang F, Geng L, Yu J, Zhou L, Yan S, Zheng S. Prognostic prediction of male recipients selected for liver transplantation: With special attention to neutrophil to lymphocyte ratio. Hepatol Res. 2016;46:899-907. [PMID: 26666880 DOI: 10.1111/hepr.12633] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
111 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 703] [Article Influence: 156.2] [Reference Citation Analysis]
112 Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 2011;17 Suppl 2:S81-S89. [PMID: 21748847 DOI: 10.1002/lt.22380] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
113 Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology. 2015;62:158-165. [PMID: 25777590 DOI: 10.1002/hep.27787] [Cited by in Crossref: 135] [Cited by in F6Publishing: 117] [Article Influence: 22.5] [Reference Citation Analysis]
114 Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103. [PMID: 22792474 DOI: 10.1155/2012/893103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
115 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(1170175-9] [Reference Citation Analysis]
116 Piñero F, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, Anders M, Zerega A, Menéndez J, Zapata R, Muñoz L, Padilla Machaca M, Soza A, McCormack L, Poniachik J, Podestá LG, Gadano A, Boin IS, Duvoux C, Silva M; Latin American Liver Research, Education and Awareness Network (LALREAN). Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int 2016;36:1657-67. [PMID: 27169841 DOI: 10.1111/liv.13159] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
117 Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009;22:869-75. [PMID: 19386075 DOI: 10.1111/j.1432-2277.2009.00882.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
118 Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014;97 Suppl 8:S10-S17. [PMID: 24849822 DOI: 10.1097/01.tp.0000446267.19148.21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
119 Bhoori S, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transpl Int. 2010;23:712-722. [PMID: 20492616 DOI: 10.1111/j.1432-2277.2010.01111.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
120 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 128] [Article Influence: 20.7] [Reference Citation Analysis]
121 Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol. 2014;20:5308-5319. [PMID: 24833861 DOI: 10.3748/wjg.v20.i18.5308] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
122 Song BG, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Kim JM, Joh JW, Choi GS. Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. Transplant Proc 2020;52:881-8. [PMID: 32115240 DOI: 10.1016/j.transproceed.2020.01.037] [Reference Citation Analysis]
123 Levi Sandri GB, Rayar M, Qi X, Lucatelli P. Liver transplant for patients outside Milan criteria. Transl Gastroenterol Hepatol 2018;3:81. [PMID: 30505968 DOI: 10.21037/tgh.2018.10.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
124 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol. 2016;22:232-252. [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
125 Li Y, Ruan D, Yi H, Wang G, Yang Y, Jiang N. A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function. Hepatobiliary & Pancreatic Diseases International 2015;14:477-84. [DOI: 10.1016/s1499-3872(15)60412-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
126 DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166-172. [PMID: 21294289 DOI: 10.1097/sla.0b013e31820508f1] [Cited by in Crossref: 170] [Cited by in F6Publishing: 87] [Article Influence: 17.0] [Reference Citation Analysis]
127 Kornberg A, Küpper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschild D, Friess H. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl. 2012;18:53-61. [PMID: 21850692 DOI: 10.1002/lt.22416] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
128 Toso C, Cader S, Mentha-Dugerdil A, Meeberg G, Majno P, Morard I, Giostra E, Berney T, Morel P, Mentha G, Kneteman NM. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci 2013;20:342-7. [PMID: 22710887 DOI: 10.1007/s00534-012-0528-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
129 Huang H, Lee F, Huo T. Major adverse events, pretransplant assessment and outcome prediction. Journal of Gastroenterology and Hepatology 2009;24:1716-24. [DOI: 10.1111/j.1440-1746.2009.06025.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
130 Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation: Alpha-Fetoprotein Increase and m RECIST Progression. Liver Transpl 2013;19:1108-18. [DOI: 10.1002/lt.23706] [Cited by in Crossref: 121] [Cited by in F6Publishing: 112] [Article Influence: 15.1] [Reference Citation Analysis]
131 Kaido T, Uemoto S. Does living donation have advantages over deceased donation in liver transplantation? J Gastroenterol Hepatol. 2010;25:1598-1603. [PMID: 20880167 DOI: 10.1111/j.1440-1746.2010.06418.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
132 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 160] [Article Influence: 28.2] [Reference Citation Analysis]
133 Hong G, Suh KS, Suh SW, Yoo T, Kim H, Park MS, Choi Y, Paeng JC, Yi NJ, Lee KW. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016;64:852-859. [PMID: 26658686 DOI: 10.1016/j.jhep.2015.11.033] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 10.7] [Reference Citation Analysis]
134 Lee YH, Hsu CY, Huang YH, Su CW, Lin HC, Hsia CY, Huo TI. α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma. J Gastrointest Surg 2013;17:730-8. [PMID: 23188220 DOI: 10.1007/s11605-012-2081-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
135 Uchiyama H, Itoh S, Yoshizumi T, Ikegami T, Harimoto N, Soejima Y, Harada N, Morita K, Toshima T, Motomura T. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years. HPB (Oxford). 2017;19:1082-1090. [PMID: 28888776 DOI: 10.1016/j.hpb.2017.08.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
136 Lai Q, Lerut JP. Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant. 2014;19:229-234. [PMID: 24811435 DOI: 10.1097/mot.0000000000000085] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
137 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
138 Ho SY, Hsu CY, Liu PH, Lee RC, Ko CC, Huang YH, Su CW, Hou MC, Huo TI. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Dig Dis Sci 2021;66:1730-8. [PMID: 32548811 DOI: 10.1007/s10620-020-06384-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
139 Piñero F, Carrihlo FJ, Silva MO. Predictive models for recurrence risk of hepatocellular carcinoma after liver transplantation: Still an unmet need. Liver Int 2017;37:648-50. [PMID: 28453922 DOI: 10.1111/liv.13417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
140 Muscari F, Guinard JP, Kamar N, Peron JM, Otal P, Suc B. Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. World J Surg. 2012;36:1824-1831. [PMID: 22532309 DOI: 10.1007/s00268-012-1587-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
141 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
142 Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? Liver Transpl 2011;17 Suppl 2:S147-58. [PMID: 21714065 DOI: 10.1002/lt.22367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
143 Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary & Pancreatic Diseases International 2016;15:234-56. [DOI: 10.1016/s1499-3872(16)60097-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
144 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
145 Lai Y, Lee JC, Hung HC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Models to predict disease-free survival for hepatocellular carcinoma patients with surgical resections. J Surg Oncol 2020;122:1444-52. [PMID: 32875573 DOI: 10.1002/jso.26169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Mehta N, Yao FY. Moving past “One size (and number) fits all” in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013;19:1055-1058. [PMID: 23959652 DOI: 10.1002/lt.23730] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
147 Végső G, Görög D, Fehérvári I, Nemes B, Doros A, Langer RM, Kóbori L. Role of Organ Transplantation in the Treatment of Malignancies – Hepatocellular Carcinoma as the Most Common Tumour Treated with Transplantation. Pathol Oncol Res 2012;18:1-10. [DOI: 10.1007/s12253-011-9441-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
148 Tanaka T, Kurosaki M, Lilly LB, Izumi N, Sherman M. Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis. J Surg Oncol 2015;112:72-9. [PMID: 26032085 DOI: 10.1002/jso.23944] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
149 Kashkoush S, El Moghazy W, Kawahara T, Gala-lopez B, Toso C, Kneteman NM. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant 2014;28:728-36. [DOI: 10.1111/ctr.12373] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
150 Lee HW, Suh K. Advancements of liver transplantation for hepatocellular carcinoma in Korea. Japanese Journal of Clinical Oncology 2017;47:93-100. [DOI: 10.1093/jjco/hyw168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
151 Kaido T, Morita S, Tanaka S, Ogawa K, Mori A, Hatano E, Uemoto S. Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study. Dis Markers 2015;2015:425926. [PMID: 25922554 DOI: 10.1155/2015/425926] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
152 Yoon YI, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000. [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
153 Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K, Krawczyk M. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 2014;38:2698-707. [PMID: 24858191 DOI: 10.1007/s00268-014-2647-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
154 Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl 2013;19:1318-23. [PMID: 24039140 DOI: 10.1002/lt.23735] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
155 Yang K, Lee T, Choi B, Park Y, Ryu J, Joo D, Chu C. Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma. Transplantation Proceedings 2016;48:3317-22. [DOI: 10.1016/j.transproceed.2016.08.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Xia W, Ke Q, Wang Y, Wang W, Zhang M, Shen Y, Wu J, Xu X, Zheng S. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation. World J Surg Oncol 2015;13:60. [PMID: 25885777 DOI: 10.1186/s12957-015-0472-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
157 Ferre-aracil C, Lledó J, Aguilera L, Garcia-paredes A, Rodríguez-santiago E, Graus J, García-gonzález M, Nuño J, López-buenadicha A, López-hervás P, Rodríguez-gandía M, Gea F, Albillos A. Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation. Digestive and Liver Disease 2018;50:1345-50. [DOI: 10.1016/j.dld.2018.04.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
158 Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014;40:893-902. [DOI: 10.1111/apt.12922] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
159 Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant. 2016;21:231-237. [PMID: 26918880 DOI: 10.1097/mot.0000000000000294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
160 Balci D, Dayangac M, Yaprak O, Akin B, Duran C, Killi R, Yuzer Y, Tokat Y. Living donor liver transplantation for hepatocellular carcinoma: a single center analysis of outcomes and impact of different selection criteria: Living donor liver transplantation for hepatocellular carcinoma. Transplant International 2011;24:1075-83. [DOI: 10.1111/j.1432-2277.2011.01311.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
161 Hu Z, Zhou J, Li Z, Xiang J, Qian Z, Wu J, Zhang M, Zheng S. Time interval to recurrence as a predictor of overall survival in salvage liver transplantation for patients with hepatocellular carcinoma associated with hepatitis B virus. Surgery 2015;157:239-48. [PMID: 25616940 DOI: 10.1016/j.surg.2014.09.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
162 Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int. 2017;37:317-327. [PMID: 27634369 DOI: 10.1111/liv.13255] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
163 Takada Y, Kaido T, Shirabe K, Nagano H, Egawa H, Sugawara Y, Taketomi A, Takahara T, Wakabayashi G, Nakanishi C, Kawagishi N, Kenjo A, Gotoh M, Toyoki Y, Hakamada K, Ohtsuka M, Akamatsu N, Kokudo N, Takeda K, Endo I, Takamura H, Okajima H, Wada H, Kubo S, Kuramitsu K, Ku Y, Ishiyama K, Ohdan H, Ito E, Maehara Y, Honda M, Inomata Y, Furukawa H, Uemoto S, Yamaue H, Miyazaki M, Takada T; LTx-PET study group of the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Liver Transplantation Society. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: A Japanese multicenter study. J Hepatobiliary Pancreat Sci. 2017;24:49-57. [PMID: 27806426 DOI: 10.1002/jhbp.412] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
164 Yilmaz C, Karaca CA, Iakobadze Z, Farajov R, Kilic K, Doganay L, Kilic M. Factors Affecting Recurrence and Survival After Liver Transplantation for Hepatocellular Carcinoma. Transplant Proc. 2018;50:3571-3576. [PMID: 30577240 DOI: 10.1016/j.transproceed.2018.05.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
165 Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, Deschênes M, Paraskevas S, Hassanain M, Tchervenkov JI. Pretransplantation α-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation 2013;95:228-33. [PMID: 23222895 DOI: 10.1097/TP.0b013e31827743d7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
166 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
167 Ogawa K, Takada Y. Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol 2016;1:35. [PMID: 28138602 DOI: 10.21037/tgh.2016.04.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
168 Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009;9:2362-2371. [PMID: 19656125 DOI: 10.1111/j.1600-6143.2009.02783.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 8.6] [Reference Citation Analysis]
169 Hibi T, Shinoda M, Itano O, Kitagawa Y. Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine. Organogenesis 2014;10:241-9. [PMID: 24836922 DOI: 10.4161/org.29245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
170 Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019;11:50-64. [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
171 Grat M, Kornasiewicz O, Hołówko W, Lewandowski Z, Zieniewicz K, Paczek L, Krawczyk M. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc 2013;45:1899-903. [PMID: 23769067 DOI: 10.1016/j.transproceed.2012.12.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
172 Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver transplantation for small hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:391-8. [PMID: 27826553 DOI: 10.21037/hbsn.2016.05.03] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
173 Toso C, Meeberg G, Andres A, Shore C, Saunders C, Bigam DL, Shapiro AMJ, Compagnon P, Berney T, Majno P, Kneteman N. Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence - a retrospective study. Transpl Int 2019;32:163-72. [PMID: 30152891 DOI: 10.1111/tri.13337] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
174 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
175 Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant. 2011;11:2031-2035. [PMID: 21831154 DOI: 10.1111/j.1600-6143.2011.03689.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
176 Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl 2018;24:369-79. [PMID: 29140601 DOI: 10.1002/lt.24977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
177 Lesurtel M, Clavien PA. 2010 International Consensus Conference on Liver Transplantation for Hepatocellular Carcinoma: texts of experts. Liver Transpl 2011;17 Suppl 2:S1-5. [PMID: 21656651 DOI: 10.1002/lt.22350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
178 Varona MA, Soriano A, Aguirre-Jaime A, Garrido S, Oton E, Diaz D, Portero J, Bravo P, Barrera MA, Perera A. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc. 2015;47:84-89. [PMID: 25645778 DOI: 10.1016/j.transproceed.2014.12.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
179 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
180 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
181 Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option? Liver Int. 2011;31:1081-1089. [PMID: 22008644 DOI: 10.1111/j.1478-3231.2011.02473.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
182 Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52:930-936. [PMID: 20385428 DOI: 10.1016/j.jhep.2009.12.032] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
183 Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer 2018;7:179-89. [PMID: 29888207 DOI: 10.1159/000487058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
184 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
185 Lee SD, Kim SH. Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2016;5:408-414. [PMID: 27826555 DOI: 10.21037/hbsn.2016.08.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
186 Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K, Takada Y, Uemoto S. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery. 2013;154:1053-1060. [PMID: 24074704 DOI: 10.1016/j.surg.2013.04.056] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 9.4] [Reference Citation Analysis]
187 Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885-900. [PMID: 32662680 DOI: 10.1080/17474124.2020.1791704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Gehrau R, Mas V, Archer KJ, Maluf D. Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. Expert Rev Gastroenterol Hepatol. 2011;5:539-552. [PMID: 21780900 DOI: 10.1586/egh.11.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
189 Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, Bain VG, Kneteman NM, Hilsden RJ. Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada. Can J Gastroenterol Hepatol 2016;2016:1329532. [PMID: 27446823 DOI: 10.1155/2016/1329532] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
190 Sacco R, Antonucci M, Bresci G, Corti A, Giacomelli L, Mismas V, Rainieri M, Romano A, Eggenhoffner R, Tumino E, Cabibbo G. Curative therapies for hepatocellular carcinoma: an update and perspectives. Expert Review of Anticancer Therapy 2016;16:169-75. [DOI: 10.1586/14737140.2016.1123625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
191 Zhao T, Jia L, Li J, Ma C, Wu J, Shen J, Dang L, Zhu B, Li P, Zhi Y, Lan R, Xu Y, Hao Z, Chai Y, Li Q, Hu L, Sun S. Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations. Front Oncol 2020;10:496. [PMID: 32426269 DOI: 10.3389/fonc.2020.00496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
192 Ren Q, Fu S, Wang D, Ju W, He X. Prognostic Value of Preoperative Serum Leucine Aminopeptidases in Hepatocellular Carcinoma Patients Who Underwent Liver Transplantation. Cancer Manag Res 2021;13:1053-66. [PMID: 33574703 DOI: 10.2147/CMAR.S292128] [Reference Citation Analysis]
193 Asrih M, Lenglet S, Mach F, Montecucco F. Alpha-fetoprotein: a controversial prognostic biomarker for small hepatocellular carcinoma. World J Gastroenterol 2013;19:328-30. [PMID: 23372353 DOI: 10.3748/wjg.v19.i3.328] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
194 Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-S57. [PMID: 21695773 DOI: 10.1002/lt.22365] [Cited by in Crossref: 320] [Cited by in F6Publishing: 282] [Article Influence: 35.6] [Reference Citation Analysis]
195 Grąt M, Stypułkowski J, Patkowski W, Wronka KM, Bik E, Krasnodębski M, Masior Ł, Lewandowski Z, Wasilewicz M, Grąt K, Krawczyk M, Zieniewicz K. Challenging the principle of utility as a barrier for wider use of liver transplantation for hepatocellular cancer. Ann Surg Oncol 2017;24:3188-95. [PMID: 28695391 DOI: 10.1245/s10434-017-5989-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
196 Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, Park SJ. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26:50-60. [PMID: 23106431 DOI: 10.1111/j.1432-2277.2012.01572.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
197 Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST, Lo CM. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl. 2013;19:411-419. [PMID: 23447460 DOI: 10.1002/lt.23605] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 8.8] [Reference Citation Analysis]
198 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
199 Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58:609-618. [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 11.0] [Reference Citation Analysis]
200 Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015;19:309-323. [PMID: 25921665 DOI: 10.1016/j.cld.2015.01.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
201 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 754] [Article Influence: 112.9] [Reference Citation Analysis]
202 Kneteman NM, Asthana S, Lewis J, Dibben C, Douglas D, Nourbakhsh M, Tyrrell LJ, Lund G. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection. Liver Transpl 2012;18:38-44. [PMID: 21837737 DOI: 10.1002/lt.22400] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
203 Guiteau JJ, Cotton RT, Washburn WK, Harper A, O’Mahony CA, Sebastian A, Cheng S, Klintmalm G, Ghobrial M, Halff G. An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant. 2010;10:2092-2098. [PMID: 20883543 DOI: 10.1111/j.1600-6143.2010.03222.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
204 Wang ZY, Geng L, Zheng SS. Current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation. Hepatobiliary Pancreat Dis Int 2015;14:145-9. [PMID: 25865686 DOI: 10.1016/s1499-3872(15)60345-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
205 de'Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol. 2015;21:11185-11198. [PMID: 26494973 DOI: 10.3748/wjg.v21.i39.11185] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 48] [Article Influence: 13.2] [Reference Citation Analysis]
206 Hu Z, Zhou J, Li Z, Xiang J, Qian Z, Wu J, Zhang M, Zheng S. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: retrospective study of the Milan and Hangzhou criteria. PLoS One. 2014;9:e87222. [PMID: 24475255 DOI: 10.1371/journal.pone.0087222] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
207 Briceño J, Ciria R, de la Mata M. Donor-recipient matching: Myths and realities. Journal of Hepatology 2013;58:811-20. [DOI: 10.1016/j.jhep.2012.10.020] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
208 Kumaran V. Role of liver transplantation for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S97-S103. [PMID: 25755618 DOI: 10.1016/j.jceh.2014.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
209 Hu Z, Li Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci 2014;59:3062-72. [PMID: 25008426 DOI: 10.1007/s10620-014-3266-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
210 Commander SJ, Shaw B, Washburn L, Yoeli D, Rana A, Goss JA. A long-term experience with expansion of Milan criteria for liver transplant recipients. Clin Transplant 2018;32:e13254. [DOI: 10.1111/ctr.13254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
211 Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl. 2012;18:423-433. [PMID: 22250078 DOI: 10.1002/lt.23385] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
212 Burak KW. Prognosis in the early stages of hepatocellular carcinoma: Predicting outcomes and properly selecting patients for curative options. Can J Gastroenterol 2011;25:482-4. [PMID: 21912758 DOI: 10.1155/2011/302457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
213 Sanchez W. Expanding transplant criteria for hepatocellular carcinoma: Small steps down a long road. Hepatology 2009;49:724-5. [DOI: 10.1002/hep.22855] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
214 de la Fuente S, Citores MJ, Lucena JL, Muñoz P, Cuervas-Mons V. TLR9-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation. Biomark Med 2019;13:995-1004. [PMID: 31317790 DOI: 10.2217/bmm-2019-0030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
215 Refaat R, Basha MAA, Hassan MS, Hussein RS, El Sammak AA, El Sammak DAEA, Radwan MHS, Awad NM, Saad El-Din SA, Elkholy E, Ibrahim DRD, Saleh SA, Montasser IF, Said H. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma. Eur Radiol. 2018;28:5356-5367. [PMID: 29948070 DOI: 10.1007/s00330-018-5425-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
216 Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant. 2015;29:506-512. [PMID: 25777321 DOI: 10.1111/ctr.12542] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
217 Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010;51:1237-1243. [PMID: 20187107 DOI: 10.1002/hep.23437] [Cited by in Crossref: 217] [Cited by in F6Publishing: 194] [Article Influence: 19.7] [Reference Citation Analysis]
218 Mullath A, Krishna M. Hepatocellular carcinoma - time to take the ticket. World J Gastrointest Surg 2019;11:287-95. [PMID: 31367276 DOI: 10.4240/wjgs.v11.i6.287] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
219 Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, Chen GH. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One 2011;6:e25295. [PMID: 21966488 DOI: 10.1371/journal.pone.0025295] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
220 Dai Z, Yu L, Zhou J, Qiu SJ, Fan J. Molecular markers and hepatocellular carcinoma: lending a helping hand in liver transplantation? Expert Rev Gastroenterol Hepatol 2009;3:211-3. [PMID: 19485802 DOI: 10.1586/egh.09.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
221 Grąt M, Wronka KM, Stypułkowski J, Bik E, Krasnodębski M, Masior Ł, Lewandowski Z, Grąt K, Patkowski W, Krawczyk M. The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer. Ann Surg Oncol 2017;24:526-34. [PMID: 27531306 DOI: 10.1245/s10434-016-5500-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
222 Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma: An Aggressive Subtype of Hepatocellular Carcinoma. American Journal of Surgical Pathology 2019;43:943-8. [DOI: 10.1097/pas.0000000000001289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]